Piper Sandler maintained an Overweight rating on Scholar Rock Holding Corporation (SRRK) on March 4, 2026, while raising its price target, according to StreetInsider. This SRRK analyst rating note is the sole public change in our dataset for this date. The update ties to recent company news and a Q4 2025 earnings briefing, and the market moved with the note, showing a 7.04% gain, equal to $3.12 since the release

SRRK analyst rating update from Piper Sandler

Piper Sandler maintained Overweight on SRRK on March 4, 2026 and signaled incremental positivity toward the shares. The firm also raised its price target per the StreetInsider note, though the headline summary did not report the exact dollar target source.

What Piper Sandler said and the price target change

Piper Sandler described a more positive view of Scholar Rock’s clinical and commercial progress and raised its price target, per the March 4 release. The note emphasizes clinical milestones and commercial readiness as drivers behind the adjusted SRRK analyst rating and target, even if the summary did not list a new numeric target.

Market reaction and SRRK stock performance

Markets responded to the Piper Sandler note with a 7.04% increase, or $3.12, in SRRK since the report time of 07:55 AM on March 4, 2026. Scholar Rock’s market cap stands at $4,838,192,010, and the price movement shows short-term sensitivity to analyst commentary.

Investor implications of an Overweight rating

An Overweight recommendation means Piper Sandler expects SRRK to outperform its sector or benchmark over the next 12 months. For investors, this SRRK analyst rating suggests increased conviction in upside from clinical progress, but it does not guarantee short-term gains or protect against trial or commercial setbacks.

Historical analyst coverage and context for SRRK

Analyst coverage for Scholar Rock has been concentrated among a small set of specialist firms, with Piper Sandler acting as a notable active voice on the stock. The March 4 action continues a pattern where clinical milestones and earnings updates drive rating moves and price target revisions.

Meyka analysis, grade, and next catalysts

Meyka AI reviews this SRRK analyst rating in the context of recent company updates, including the Q4 2025 earnings call and R&D progress source. Meyka AI rates SRRK with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Investors should watch upcoming clinical readouts and commercial milestones as the next catalysts.

Final Thoughts

Piper Sandler’s March 4, 2026 note maintained an Overweight stance on Scholar Rock (SRRK) and raised its firm price target, a move tied to improving commercial readiness and clinical progress. The market reacted with a 7.04% lift, or $3.12, reflecting short-term investor enthusiasm. Our SRRK analyst rating review places that action into a broader picture: analyst commentary remains a key price driver for this name, given its biotech profile and event-driven risk. Meyka AI rates SRRK with a grade of B+. This grade reflects comparisons to the S&P 500, sector peers, recent financial growth, key operational metrics, and the prevailing analyst consensus. These grades are not guaranteed and are not financial advice. Investors should weigh the Overweight opinion alongside trial timelines, commercial execution, and their personal risk tolerances. For regular, real-time tracking of analyst moves and data-driven context, consult our Meyka AI-powered market analysis platform and the SRRK stock page

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.